Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Obesity SURMOUNT-1 Trial In adults with obesity (without diabetes): Tirzepatide (15 mg) : 20.9% average body weight reduction over 72 weeks Semaglutide (2.4 mg) (based on STEP trials): ~14.9% average reduction STEP 5 Long-Term Results Semaglutide also demonstrated durable effects: At 104 weeks, patients maintained ~15% weight loss on semaglutide 2.4 mg (STEP 5) SELECT Trial Cardiovascular Benefit Semaglutide significantly reduced major adverse cardiovascular events by 20% in people with obesity and pre-existing heart diseaseindicating benefit beyond weight loss
in doing so, it helps reduce appetite, increase fullness, and boost calorie burn
Fatigue and reduced motivation may also arise indirectly through several pathways
Wegovy, with the active ingredient semaglutide, is a once-weekly GLP-1 medication delivered via a pre-filled injection pen or daily tablet
Experts link the drug's weight reduction outcomes primarily to appetite suppression via action on the hypothalamic GLP-1 receptor
